Two papers reported that HDACi treatment enhanced the effect of anti-PD1 immunotherapy in melanoma through diverging molecular mechanisms: Woods and colleagues [165] found that inhibition of class I HDAC increases the expression of PD-L1 and PD-L2 ligands, while Booth and colleagues [166] observed a downregulation of PD-L1 and PD-L2 and an upregulation of class I MHC protein MHCA, following treatment with pan-HDAC inhibitors. The gene discussed is PDCD1LG2; the disease is melanoma.